Trastuzumab was radiolabeled with 125I to high specific activity and competition binding assays were performed on HER2-amplified human breast carcinoma lines SK-BR-3, KPL-4 and BT-474 and DHFR-G8. The gene discussed is ERBB2; the disease is breast carcinoma.